Lyell Immunopharma Inc Quick Ratio (LYEL) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Lyell Immunopharma Inc   (NASDAQ: LYEL)

Lyell Immunopharma Inc 's Quick Ratio

LYEL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 5.12 below Lyell Immunopharma Inc average.

Within Major Pharmaceutical Preparations industry 186 other companies have achieved higher Quick Ratio than Lyell Immunopharma Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 466 to 695.

Explain Quick Ratio?
How much Cash & cash equivalents LYEL´s has?
What are LYEL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LYEL Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 8.03 % -10.51 % -35.93 % -4.88 % 19.51 %
Y / Y Cash & cash equivalent Change -26.26 % -15.66 % -33.28 % -27.45 % -43.64 %
Quick Ratio MRQ 5.12 6.88 5 10.03 7.5
LYEL's Total Ranking # 695 # 466 # 462 # 288 # 337
Seq. Current Liabilities Change 7.9 % -25.23 % 55 % -13.62 % -10.61 %
Seq. Cash & cash equivalent Change -19.65 % 2.75 % -22.65 % 15.48 % -8.1 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 187
Healthcare Sector # 298
Overall Market # 695


Quick Ratio Statistics
High Average Low
19.9 12.25 5
(Mar 31 2023)   (Dec 31 2025)




Financial Statements
Lyell Immunopharma Inc 's Current Liabilities $ 40 Millions Visit LYEL's Balance sheet
Lyell Immunopharma Inc 's Cash & cash equivalent $ 204 Millions Visit LYEL's Balance sheet
Source of LYEL's Sales Visit LYEL's Sales by Geography


Cumulative Lyell Immunopharma Inc 's Quick Ratio

LYEL's Quick Ratio for the trailling 12 Months

LYEL Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -16.27 % -15.13 % -8.28 % 42.61 % 42.17 %
Y / Y Cash & cash equivalent TTM Growth -26.21 % -31.54 % -37.39 % -36.73 % -35.06 %
Quick Ratio TTM 6.48 7.08 7.18 6.77 7.36
Total Ranking TTM # 3576 # 3510 # 2311 # 2735 # 2614
Seq. Current Liabilities TTM Growth 1.91 % -2.72 % -14.8 % -0.87 % 3.3 %
Seq. Cash & cash equivalent TTM Growth -6.62 % -4.12 % -9.72 % -8.71 % -13.37 %

Quick ratio ranking by company, industry and sector >> Back to LYEL Financial Strength Comparisons >> Go to Compare LYEL Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2026 to $39.87 millions, cumulative Quick Ratio decreased to 6.48 below the Lyell Immunopharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 423 other companies have achieved higher Quick Ratio than Lyell Immunopharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3510 to 3576.

Explain Quick Ratio?
How much Cash & cash equivalents LYEL´s has?
What are LYEL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 424
Healthcare Sector # 861
Within the Market # 3576


trailing twelve months Quick Ratio Statistics
High Average Low
17.66 12.43 6.48
(Sep 30 2023)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
An2 Therapeutics Inc   14.04 $ 78.387  Millions$ 5.585  Millions
Aclaris Therapeutics Inc   13.97 $ 394.443  Millions$ 28.241  Millions
Pmv Pharmaceuticals Inc   13.85 $ 146.393  Millions$ 10.568  Millions
Generate Biomedicines Inc   13.76 $ 779.456  Millions$ 56.636  Millions
First Tracks Biotherapeutics Inc   13.50 $ 168.018  Millions$ 12.447  Millions
Arrivent Biopharma inc   13.41 $ 373.401  Millions$ 27.844  Millions
Cogent Biosciences Inc   13.36 $ 792.300  Millions$ 59.296  Millions
Aprea Therapeutics Inc   13.33 $ 41.233  Millions$ 3.092  Millions
Polaryx Therapeutics Inc   13.22 $ 11.542  Millions$ 0.873  Millions
Monopar Therapeutics Inc   13.14 $ 52.758  Millions$ 4.016  Millions
Lexicon Pharmaceuticals Inc   12.96 $ 190.610  Millions$ 14.706  Millions
Korro Bio Inc   12.89 $ 162.805  Millions$ 12.628  Millions
Atea Pharmaceuticals Inc   12.89 $ 362.382  Millions$ 28.124  Millions
Oric Pharmaceuticals Inc   12.76 $ 264.761  Millions$ 20.756  Millions
Diamedica Therapeutics Inc   12.42 $ 81.875  Millions$ 6.594  Millions
Vtv Therapeutics Inc   12.35 $ 86.643  Millions$ 7.017  Millions
Theravance Biopharma inc   12.30 $ 378.546  Millions$ 30.766  Millions
Coya Therapeutics Inc   12.29 $ 43.181  Millions$ 3.512  Millions
Bridgebio Oncology Therapeutics Inc   12.28 $ 634.167  Millions$ 51.634  Millions
Ocular Therapeutix Inc   12.17 $ 598.641  Millions$ 49.174  Millions
Wave Life Sciences Ltd   12.07 $ 613.194  Millions$ 50.815  Millions
Amylyx Pharmaceuticals Inc   11.86 $ 250.760  Millions$ 21.150  Millions
Moonlake Immunotherapeutics  11.83 $ 537.000  Millions$ 45.392  Millions
Eledon Pharmaceuticals Inc   11.77 $ 170.753  Millions$ 14.503  Millions
Tyra Biosciences Inc   11.76 $ 354.060  Millions$ 30.106  Millions
Opus Genetics Inc   11.69 $ 88.912  Millions$ 7.605  Millions
Aardvark Therapeutics Inc   11.57 $ 73.921  Millions$ 6.387  Millions
Dyne Therapeutics Inc   11.51 $ 898.475  Millions$ 78.029  Millions
Evommune Inc   11.50 $ 201.014  Millions$ 17.487  Millions
Bicara Therapeutics Inc   11.44 $ 497.259  Millions$ 43.475  Millions

Date modified: 2026-09-08T20:47:26+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.